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The history of incessant struggle and the current global burden associated with emerging infectious disease especially 
tuberculosis, guided us to define the scope of this research project, and to identify research gaps in synthesizing some 
heterocyclic compounds for anti-tubercular activity. In this research project, we have synthesized a series of novel 
heterocyclic (benzothiazoles) compounds viz N'-((1-(7-chloro-6-fluorobenzo[d]thiazol-2-yl)-3-phenyl-1H-pyrazol-4-yl) 
methylene)isonicotinohydrazide 12a-c their 5-nitro 15a-c and 4-nitro 18a-c derivatives, by a series of reactions of their 
respective synthons. The completion of reaction and the purity of the synthesized compounds have been established by 
chromatographic analysis. All the newly synthesized compounds satisfactorily show acceptable analysis for their anticipated 
structures, which have been confirmed based on physicochemical and spectral data. These newly synthesized compounds 
have been primarily evaluated for their in vitro anti-tubercular activity by Ziehl-Neelsen stain method. Compounds 15a, 
15b, 15c, 18b and 18c have shown 100% inhibition at 25 mg/ mL and MIC values of around 45 nM against M. tuberculosis 
H37Rv (ATCC 27294). Cytotoxicity on THP-1 cell line shows that all the tested compounds are safe. 
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Bacterial resistance to antibacterial agents or 
antibiotics is of serious concern in the medical 
community, as many species of bacteria have evolved 
resistance to certain well known antibiotics and 
synthetic agents. Therefore, there could be a rapidly 
growing global crisis in the clinical management of 
life-threatening infectious diseases caused by 
multidrug-resistant strains. To meet this catastrophe 
successfully, many researchers across the globe are 
working to discover new compounds which can 
selectively attack novel targets in microorganisms. 
Hence, the development of novel, potent, and unique 
antibacterial agents is the supreme way to overcome 
bacterial resistance and develop effective therapies. 
Agents that reduce the duration and complexity of the 
current therapy would have a major impact on the 
overall cure rate, meaning, there is an urgent need for 
new antimycobacterials
1
. In India, each year, approx. 
220,000 deaths are reported due to tuberculosis. India 
is the highest TB burden country with World Health 
Organisation (WHO) statistics for 2011 giving an 
estimated incidence figure of 2.2 million cases of TB 
for India out of a global incidence of 9.6 million 
cases
2,3
. Tuberculosis is India's biggest health issue, 
but what makes this issue worse is the recently 
discovered phenomenon of Totally Drug-Resistant 
Tuberculosis (TDR-TB). This issue of drug-resistant 
TB began with Multi Drug-Resistant Tuberculosis 
(MDR-TB), and moved on to Extremely Drug 
Resistant Tuberculosis (XDR-TB). Gradually, the 
most dangerous form has situated itself in India as 
TDR-TB. We have previously reported that certain 
benzothiazoles especially nitro benzothiazoles have 
good anti-tubercular activity
4
. These compounds 
exhibit several properties which make them highly 
interesting as potential drugs against tuberculosis. It 
has been estimated that approximately 30 million 
people will die from tuberculosis in about ten years. 
Benzothiazole derivatives are found in commercial 
products in nature. A derivative of benzothiazole is 
the light-emitting component of luciferin, found in 
fireflies. Pyrazole is extensively used as useful 
synthons in organic syntheses. INH, when it is 
attached to the benzothiazole derivatives the anti 
tubercular activity of the compounds will altered. 
Compounds containing nitro groups (nitrophenols, 
nitrobenzenes and nitrofurans) possess high 
physiological activity. Chloramphenicol, nitrofurans 




are the very good antibiotics available in the  
market contains nitro aromatic in the structure
5
. In the 
recent years nitrobenzothiazole has been discovered 




Fluorine has been incorporated into the benzothiazole 
molecule. Because, being the second smallest substituent 
next to hydrogen, intimately mimics hydrogen in 
enzyme receptor interactions. The substitutions of 
fluorine by hydrogen increases lipophilicity which in 
turn increases the transport and absorption of drug 
in vivo, and a strong electron withdrawing inductive 
effect of fluorine can significantly influence reactivity 





Results and Discussion 
 
Chemistry 
In the course of our ongoing program devoted to 
the synthesis of some nitro benzothiazoles as anti-
tubercular activity we describe the synthesis of N'-((1-
(7-chloro-6-fluorobenzo[d]thiazol-2-yl)-3-phenyl-1H-
pyrazol-4-yl)methylene)isonicotinohydrazide (12a-c) 
their 5-nitro (15a-c) and 4-nitro (18a-c) derivatives 
through the versatile and efficient synthetic route 
outlined in Scheme I, Scheme II, Scheme III and 
Scheme IV. In Scheme I, we describe the synthesis of 
7-chloro-6-fluoro-2-hydrazinylbenzo [d] thiazole (9) 
and their 5 nitro (7) and 4 nitro (8) derivatives. The 
compound 1 was synthesized from 4-fluoro-3-chloro 
aniline and potassium thiocyanate with bromine in 
acetic acid at 5ºC. The starting material then was 
treated with hydrazine hydrate and conc. HCl in the 
presence of ethylene glycol yielding compound 9. 
Alternatively the compound 1 was treated with acetic 
anhydride to protect the primary amino group  
and generate compound 2, which upon nitration with 
conc. HNO3 and conc. H2SO4 produce 3 and 4 two 
regioisomers. Compounds 3 and 4 separately 
deprotected by using 70% H2SO4 to obtain compounds 
 
 
Scheme I — Synthetic route of 7-chloro-6-fluoro-2-hydrazinylbenzo[d]thiazole 9 and 5 and 4 nitro derivatives 7 and 8. 




5 and 6. These were further treated with hydrazine 
hydrate and conc. HCl in the presence of ethylene 
glycol to obtain compounds 7 and 8 respectively. The 
NMR spectra (in DMSO-d6) of compound 7 showed 
absorption of 4
th
 proton at δ 7.89 - 7.91 ppm as doublet 
due to C–F coupling accounting for 1 proton, J = 7.62 
Hz, NH at δ 9.18 - 9.20 ppm triplet accounting for  
1 proton and NH2 at δ 5.05 ppm as doublet, accounting 
for 1 proton. Whereas compound 8 showed (in 
DMSO-d6) absorption of 5
th
 proton at δ 8.53– 
8.55 ppm as doublet due to C–F coupling accounting 
for 1 proton, J = 9.42 Hz, NH at δ 12.16 - 12.18 ppm 
as singlet accounting for 1 proton and NH2 at  
δ 5.10 ppm as doublet accounting for 1 proton.  
In Scheme II, we describe the synthesis of N'-((1-
(7-chloro-6-fluorobenzo [d] thiazol-2-yl)-3-phenyl-
1H-pyrazol-4-yl) methylene) isonicotino hydrazide 
(12a-c) derivative. The compound 10 (a-c) was 
synthesized from compound 9 was treated with 
substituted acetophenone Syntheses of N'-((1-(7-
chloro-6-fluorobenzo[d]thiazol-2-yl)-3-phenyl-1H-
pyrazol-4-yl)ethylene) isonicotino hydrazide (12a-c), 
their 5-nitro (15a-c) and 4-nitro (18a-c) derivatives 
were achieved through the versatile and efficient 
 
 





Scheme III — Synthetic route of a novel series of N'-((1-(7-chloro-6-fluoro-5-nitrobenzo [d] thiazol-2-yl)-3-substituted phenyl-1H-
pyrazol-4-yl)methylene)isonicotinohydrazide 15a-c 
 




synthetic route outlined in Scheme II, Scheme I and 
Scheme IV respectively. Compound 7-chloro-6-
fluoro-2-(2-(1-substituted phenylethylidene)hydrazinyl) 
benzo[d]thiazole (10a-c), their 5-nitro (13a-c) and 4-
nitro (16a-c) derivatives were synthesized by reacting 
7-chloro-6-fluoro-2-hydrazinylbenzo[d]thiazole (9), 
its 5-nitro (7) and 4-nitro (8) derivatives with 
substituted acetophenone in methanol with 2-3 drops 
of glacial acetic acid. Absence of primary amine  peak  
and the presence on N=C peak at around 1550 in IR 
confirmed the formation of the product. In 
1
H NMR a 
singlet peak for methyl proton at δ 2.3 accounting 
three protons, benzothiazole and aromatic protons at 
aromatic region and the absent of NH2 peak confirmed 
the product. These compounds [10(a-c), 13(a-c) and 
16(a-c)] were then subjected to Vilsmeier-Haack 
reagent prepared from DMF and POCl3 at 60-65°C to 
form 1-(7-chloro-6-fluorobenzo [d] thiazol-2-yl)-3-
substituted phenyl-1H-pyrazole-4-carbaldehyde (11a-c) 
their 5-nitro (13a-c) and 4-nitro (17a-c) derivatives. 
Preliminary conformation was done by TLC, melting 
point and overlapping IR. A strong C=O peak for 
aldehyde and the lacking of secondary amine peak in 
IR spectra confirmed the desired product. Two singlet 
peak for aldehydic and pyrazole proton at around δ 
10.0 and δ 9.5, and the nonappearance of secondary 
amine and methyl protons confirmed the formation of 
the desired product. Latter these compounds were 
treated with isoniazid in toluene with 2-3 drops of 
glacial acetic acid in Dean-Stark apparatus. Isoniazid 
tablet was dissolve in water, filter and filtrate was 
recrystallized by adding few drops of ethanol. In IR 
spectra presence of C=O, N=CH and secondary amine 





C NHR and mass spectra. In 
1
H NMR, a singlet peak for NH at around δ 12.0, 
N=CH at around δ 8.6 accounting one proton each, 
pyridine protons at around δ 8.7 and 7.7 as doublet 
and benzothiazole and aromatic protons at aromatic 
region confirmed the desired product. In 
13
C NHR 
peaks appeared at around δ 161 for C=O, pyridine 
carbons at around δ 156, 157, 140, 132 and 130, 
N=CH carbon at around δ 150 and other carbons 




The in vitro anti tubercular activity of compounds 
12a-c, 15a-c and 18a-c were screened against 
Mycobacterium tuberculosis H37Rv (ATCC 27294) 
using Middlebrook 7H-9 broth. The ability of 
compounds to inhibit the growth of Mycobacterium 
species was determined by Ziehl-Neelsen staining. 
The minimum inhibitory concentration (MIC) was 
defined as the minimum concentration of compound 
required to completely inhibit bacterial growth. 
 The MICs of the synthesized compounds along with 
the standard pyrazinamide and streptomycin drugs are 
mentioned in Table I. Nine novel synthesized 
compounds along with two standard drugs were 
 
 
Scheme IV — Synthetic route of a novel series of N'-((1-(7-chloro-6-fluoro-4-nitrobenzo [d]thiazol-2-yl)-3-substituted phenyl-1H-
pyrazol-4-yl)methylene)isonicotinohydrazide 18a-c 
 




screened for antimycobacterial activity. Three 
different final concentrations 25, 50, 100 µg/ mL of 
compounds were prepared and used for activity.  
The appearance of turbidity was considered as growth 
and indicates resistance to the compound. The growth 
was confirmed by making a smear from each bottle 
and performing a Ziehl-Neelsen stain. From the 
results it has been observed that compounds 15a, 15b, 
15c, 18b and 18c were shown 100% inhibition at  
25 mg/ mL and MIC values of around 40 nM against 
M. tuberculosis H37Rv. Whereas the standard drug 
pyrazinamide and streptomycin have been showed 
100% inhibition at 60 nM and 14 nM respectively. 
Presence nitro group increases the antitubercular 
activity irrespective of the position in benzothiazole ring. 
Only electron withdrawing substituent in this series were 
synthesized and screened, so activity towards the 
electron donating substituent yet to be carried out.  
The IC50 values of all the tested nine compounds 
were ranging from 160 to 653 nM. Presence of a nitro 
group in to the compound increases the toxicity of the 
compound. Nitro group at position 5
th
 exhibited more 
toxic than when it is in 4
th
 position, though this 
concentration is far more than the concentration tested 
for the antitubercular activity. Cytotoxicity on THP-1 
cell line showed that all the tested compounds are safe. 
 
Experimental Section 
The research chemicals and reagents were 
purchased from Himedia, Rankem, Loba chem., 
Merck, Spectrochem, SD Fine (India), Sigma-Aldrich 
(St. Louis, Missouri, USA), Lancaster Co. (Ward Hill, 
MA, USA) used as such for the reactions. Solvents, 
except laboratory reagent (LR) grade were dried and 
purified according to the literature when necessary. 
Reactions were monitored and purity of compounds 
was examined by thin layer chromatography (TLC) 
on pre-coated silica gel plates from E. Merck and Co. 
(Darmstadt, Germany). Compounds visualized on UV 
cabinet at 365 nm/ 254 nm, exposure to iodine 
vapours, different visualising reagent depending on 
the requirement. 
The melting points were determined with an 
electrothermal melting point apparatus and were 
uncorrected. Infrared spectra (KBr disc) were 
performed on FTIR-8400 Shimadzu and the 




H NMR and 
13
C 
NMR spectra were recorded on Bruker-Avance  
400 MHz instrument with TMS (0 ppm) as an internal 
standard; the chemical shifts (δ) are reported in ppm 
and coupling constants (J) are given in Hertz (Hz). 
Signal multiplicities are represented by s (singlet),  
d (doublet), t (triplet), dd (double doublet), m 
(multiplet) and br s (broad singlet). Mass spectra were 
recorded on ESI-MS, Thermo, Finnigan LCQ deca xp 
max. The purity of the compounds was checked on 
Merck precoated silica gel 60 F-254. Column 
chromatography was performed using P.D. fine chem. 
silica gel (100-200 mesh). Yields were not optimized. 
All the solvents and reagents were used without 
further purification. 
 
Synthesis of compound 1 
To glacial acetic acid (40 mL) precooled at 5˚C 
were added (40 g, 0.4123 mol) potassium thiocyanate 
and (7.25 g, 0.0498 mol) 4-fluoro-3-chloro aniline. 
The mixture was stirred while 6 mL of bromine in 24 
mL of glacial acetic acid was added at such a rate that 
the temperature did not rise beyond 5˚C, for a period 
of 2 h. The stirring was continued for an additional  
2 h at the same temperature, and at room temperature 
for 10 h. It was allowed to stand overnight during 
Table I — In vitro anti-tubercular and cytotoxicity evaluation 
S.No Compd R R1 Anti-tubercular  (MIC in nM) Cytotoxicity (IC50 nM) 
1 12a H H 104.84 645.879 
2 12b 2,4-dichloro H 91.60 641.260 
3 12c 4-fluoro H 101.03 653.733 
4 15a H 5-NO2 47.90 162.863 
5 15b 2,4-dichloro 5-NO2 42.31 160.798 
6 15c 4-fluoro 5-NO2 46.30 168.317 
7 18a H 4-NO2 95.80 469.429 
8 18b 2,4-dichloro 4-NO2 42.31 495.650 
9 18c 4-fluoro 4-NO2 46.30 555.658 
10 Pyrazinamide − − 60.095 NT 
11 Streptomycin − − 14.387 NT 
NT: Not tested, MIC: Minimum inhibitory concentration. IC50: Concentration of test compound needed to inhibit cell growth by 50%. 
 




which an orange precipitate settled at the bottom.  
30 mL of water was added and slurry was heated at 
85˚C on a water bath and filtered hot. The filtrate was 
cooled and neutralized with strong ammonia solution 
to pH 6, a light yellow precipitate was collected. The 
resulting product was recrystallized by toluene. 
7-Chloro-6-fluorobenzo[d]thiazol-2-amine, 1: 
Yield: 87%; m.p.: 180-182˚C; slight yellowish 
crystalline solid; IR (υmax, cm
-1
, KBr): 3480 (N-H), 
1247 (C-F), 1094 (C-Cl); 
1
H NMR (400MHz, DMSO-
d6), δ (ppm): 4.21 (s, 2H, NH2), 7.60-7.62 (d, 1H, J = 
7.22, ArH), 7.64-7.66 (d, 1H, ArH, J = 8.59 Hz); ESI-




; Anal. calcd. 
for C7H4ClFN2S: C, 41.49; H, 1.99; N, 13.82. Found: 
C, 41.51; H, 2.03; N, 13.81. 
 
Synthesis of compound 2 
A mixture of compound 1 (2.025 g, 0.01 mol) and 
10 mL of acetic anhydride was refluxed for 1 h. The 
reaction mixture was cooled; solid separated out, was 
boiled with water, filtered and washed with water. 
The product was then recrystallized with ethanol. 
N-(7-Chloro-6-fluorobenzo[d]thiazol-2-yl) 
acetamide, 2: Yield: 92%, m.p.: 232-233˚C, white 
star shaped crystalline solid; IR (υmax, cm
-1
, KBr): 
3318 (N-H), 1681 (C=O), 1239 (C-F), 1082 (C-Cl); 
1
H NMR (400MHz, DMSO-d6), δ (ppm): 2.34 (s, 3H, 
CH3), 7.61-7.63 (d, 1H, ArH, J = 8.67 Hz), 7.73-7.75 





; Anal. calcd. for 
C9H6ClFN2OS: C, 44.18; H, 2.47; N, 11.45. Found: C, 
44.17; H, 2.49; N, 11.44. 
 
Synthesis of compound 3 and 4 
A mixture of compound (2) (100 mg, 0.000409 mol) 
and 0.3 mL of ice cold conc. H2SO4 was stirred under 
ice cold condition. To this 0.1 mL conc. HNO3 was 
added drop wise, continued stirring at room 
temperature for 2 h. Then 0.1 mL conc. HNO3 was 
further added to the reaction mixture and stirred 
overnight at room temperature. The reaction mixture 
was poured into a large amount of water. The solids 
obtained were filtered and washed with water 
thoroughly and dried under vacuum. The compound 
obtained was a mixture of 3 and 4, which was 
separated by column chromatography employing  
n-hexane/ethyl acetate (9:1) as an eluent. 
N-(7-Chloro-6-fluoro-5-nitrobenzo[d]thiazol-2-yl) 
acetamide, 3: Yield: 56%; m.p.: 297-298˚C; buff 
colour needle shaped crystalline solid; IR (υmax, cm
-1
, 
KBr): 3301 (N-H), 1535, 1337 (NO2), 1680 (C=O), 
1186 (C-F), 661 (C-Cl); 
1
H NMR (400MHz, DMSO-
d6), δ (ppm): 2.34 (s, 3H, CH3), 7.93-7.95 [d, 1H, 





; Anal. calcd. for 
C9H5ClFN3O3S: C, 37.32; H, 1.74; N, 14.51. Found: 
C, 37.30; H, 1.76; N, 14.50. 
N-(7-Chloro-6-fluoro-4-nitrobenzo[d]thiazol-2-yl) 
acetamide, 4: Yield: 30%; m.p.: 336-337˚C; white 
crystalline solid; IR (υmax, cm
-1
, KBr): 3311 (N-H), 
1530, 1341 (NO2), 1680 (C=O), 1245 (C-F), 1092  
(C-Cl); 
1
H NMR (400MHz, DMSO-d6), δ (ppm): 2.27 
(s, 3H, CH3), 8.40-8.38 [d, 1H, ArH, J = 9.44 Hz  





; Anal. calcd. for C9H5ClFN3O3S: C, 
37.32; H, 1.74; N, 14.51. Found: C, 37.31; H, 1.76; N, 
14.52. 
 
Synthesis of compound 5 and 6 
Compounds 3 and 4 (1 g, 0.004040 mole), 
separately taken in two different round bottom flask, 
add 70% H2SO4 in both flask and was refluxed for 30 
min. Then poured the clear solution into 50 mL of 
cold water and neutralized it with dil. sodium 
hydroxide solution. Filter the solid product and 
recrystallized both product with DMF- water mixture. 
7-Chloro-6-fluoro-5-nitrobenzo[d]thiazol-2-
amine, 5: Yield: 76%; m.p.: 187-188˚C; light 
yellowish needle shaped crystalline solid; IR  
(υmax, cm
-1
, KBr): 3450 (N-H), 1543, 1348 (NO2) 
1243 (C-F), 1089 (C-Cl); 
1
H NMR (400MHz, DMSO-
d6), δ (ppm): 4.26 (s, 2H, NH2), 7.90-7.92 (d, 1H,  





; Anal. calcd. for C7H3ClFN3O2S: C, 33.95; H, 
1.22; N, 16.97. Found: C, 34.07; H, 1.21; N, 16.95. 
7-Chloro-6-fluoro-4-nitrobenzo[d]thiazol-2-
amine, 6: Yield: 94%; m.p.: 193-194˚C; yellowish 
needle shaped crystalline solid; IR (υmax, cm
-1
, KBr): 
3452 (N-H), 1550, 1333 (NO2) 1247 (C-F), 1087  
(C-Cl); 
1
H NMR (400MHz, DMSO-d6), δ (ppm): 4.29 
(s, 2H, NH2), 8.40-8.42 (d, 1H, J = 9.42, ArH);  





calcd. for C7H3ClFN3O2S: C, 33.95; H, 1.22; N, 
16.97. Found: C, 34.01; H, 1.23; N, 16.91. 
 
Synthesis of compound 7, 8 and 9 
10 ml of conc. HCl was added drop-wise with 
stirring to 10 ml (0.3 mol) hydrazine hydrate at  
5-10 ˚C followed by ethylene glycol 40 ml. To the 
above solution 0.01 mol of compound (1, 5 and 6), in 
portion was added (in separate RBF) and the resulting 
mixture was refluxed for 2 h. On cooling solid 




separated out, was filtered and washed with water, 
dried and recrystallized from ethanol. 
7-Chloro-6-fluoro-2-hydrazinyl-5-nitrobenzo[d] 
thiazole, 7: Yield 66%, m.p.: 257-258°C, gray 
coloured crystals, ): 3458 (N-H), 1542, 1349 (NO2) 
1241 (C-F), 1085 (C-Cl); 
1
H NMR (400MHz, DMSO-
d6), δ (ppm): 5.05 (s, 2H, NH2), 7.89-7.91 (d, 1H, J = 





; Anal. calcd. for 
C7H4ClFN4O2S: C, 32.01; H, 1.54; N, 21.33. Found: 
C, 32.03; H, 1.55; N, 21.35. 
7-Chloro-6-fluoro-2-hydrazinyl-4-nitrobenzo[d] 
thiazole, 8: Yield 66%, m.p.: 292-294°C, gray 
coloured crystals; IR (ν, cm
-1
, KBr): 3412 (N-H), 
1532, 1342 (NO2), 1232 (C-F), 1074 (C-Cl); 
1
H NMR 
(400MHz, DMSO-d6), δ (ppm): 5.10 (s, 2H, NH2), 
8.53-8.55 (d, 1H, J = 9.42 Hz, ArH), 12.16-12.18 (t, 





Anal. calcd. for C7H4ClFN4O2S: C, 32.01; H, 1.54; N, 
21.33. Found: C, 32.04; H, 1.55; N, 21.34. 
Synthesis of 7-chloro-6-fluoro-2-hydrazinyl 
benzo[d]thiazole, 9: Yield 66%, mp 217-219 ˚C, 
light brown coloured needle shaped crystals; IR (υmax, 
cm
-1
, KBr): 3380 (N-H), 1200 (C-F), 683 (C-Cl); 
1
H 
NMR (400MHz, DMSO-d6), δ (ppm): 5.09 (s, 2H, 
NH2), 7.42-7.41 (d, 1H, ArH, J = 6.64 Hz), 7.81-7.79 





; Anal. calcd. for 
C7H5ClFN3S: C, 38.63; H, 2.32; N, 19.31. Found: C, 
38.61; H, 2.34, N, 19.31. 
 
Synthesis of compound 10a-c 
A mixture of compound 9 (0.01 mol) and 
appropriate acetophenone (0.01 mol) in methanol  
(30 mL) containing 2-3 drop of glacial acetic acid was 
refluxed for 0.5 h. The reaction was monitored by 
TLC. After completion of the reaction, solid that 
separated out on cooling, was filtered and 
recrystallized by methanol. 
7-Chloro-6-fluoro-2-(2-(1-phenylethylidene) 
hydrazinyl)benzo[d]thiazole, 10a: Yield 92%; m.p.: 
120-122°C; colourless needle shaped crystals; IR  
(ν, cm
-1
, KBr): 3432 (NH), 1610 (N=C), 1195 (C-F), 
1028 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6),  
δ (ppm): 2.34 (s, 3H, CH3), 7.39-7.47 (m, 5H, ArH), 
7.61-7.63 (d, 1H, benzothiazole, J = 7.24 Hz), 7.65-
7.68 (d, 1H, benzothiazole, J = 8.61 Hz) 10.75 (s, 1H, 





Anal. calcd. for C15H11ClFN3S: C, 56.34; H, 3.47; N, 
5.94. Found: C, 56.33; H, 3.49, N, 5.91. 
7-Chloro-2-(2-(1-(2,4-dichlorophenyl)ethylidene) 
hydrazinyl)-6-fluorobenzo [d]thiazole, 10b: Yield 
95%; mp 192-194°C; colourless needle shaped 
crystals; IR (ν, cm
-1
, KBr): ): 3142 (NH), 1612 (N=C), 
1190 (C-F), 1030 (C-Cl); 
1
H NMR (400 MHz, 
DMSO-d6), δ (ppm): 2.37 (s, 3H, CH3), 7.42-7.44  
(m, 3H, ArH), 7.78-7.79 (d, 2H, benzothiazole), 10.76 





; Anal. calcd. for C15H9Cl3FN3S: C, 46.35; H, 
2.33; N, 10.81. Found: C, 46.33; H, 2.34, N, 10.79. 
7-Chloro-6-fluoro-2-(2-(1-(4-fluorophenyl) 
ethylidene)hydrazinyl)benzo[d] thiazole, 10c: Yield 
95%; m.p.: 224-226°C; colourless crystalline solid; IR 
(ν, cm
-1
, KBr): 3180 (N-H), 1610 (N=C), 1212 (C-F), 
1080 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ 
(ppm): 2.37 (s, 3H, CH3), 7.41-7.43 (m, 4H, ArH), 
7.78-7.79 (d, 2H, benzothiazole), 10.75 (s, 1H, NH); 





calcd. for C15H10ClF2N3S: C, 53.34; H, 2.98; N, 12.44. 
Found: C, 53.33; H, 2.99, N, 12.40. 
 
Synthesis of compound 11a-c 
To the Vilsmeier-Haack reagent prepared from 
DMF (10 mL) and POCl3 (1.1 mL, 0.012 mol), 
hydrazone 10(a-c) (0.01 mol) was added and the 
reaction mixture was stirred at 60-65°C for 3 h. The 
reaction was monitored by TLC. After completion of 
the reaction, the mixture was then poured in to ice 
cold water. The solid that separated on neutralization 
with NaHCO3 was filtered, washed with water and 
recrystallized from DMF-water. 
1-(7-Chloro-6-fluorobenzo[d]thiazol-2-yl)-3-
phenyl-1H-pyrazole-4-carbaldehyde, 11a: Yield 
84%; m.p.: 185-186°C; gray coloured solid; IR  
(ν, cm
-1
, KBr): 1691(C=O), 1203 (C-F), 1078 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 7.28- 
7.32 (m, 5H, ArH), 7.63-7.64 (d, 1H, benzothiazole,  
J =7.23 Hz), 7.69-7.71(d, 1H, benzothiazole,  
J = 8.55 Hz) 9.45 (s, 1H, pyrazole), 9.95 (s, 1H, 





Anal. calcd. for C17H9ClFN3OS: C, 57.07; H, 2.54; N, 
11.74. Found: C, 57.09; H, 2.57, N, 11.71. 
1-(7-Chloro-6-fluorobenzo[d]thiazol-2-yl)-3-
(2,4-dichlorophenyl)-1H-pyrazole-4-carbaldehyde, 
11b: Yield 84%; m.p.: 120-123°C; gray coloured 
solid; IR (ν, cm
-1
, KBr): 1692 (C=O), 1145 (C-F), 
1027 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ 
(ppm) 7.28-7.31 (m, 3H, ArH), 7.61-7.64 (d, 1H, 
benzothiazole, J = 7.24 Hz), 7.66-7.68 (d, 1H, 
benzothiazole, J = 8.60 Hz) 9.51 (s, 1H, pyrazole), 









; Anal. calcd. for C17H7Cl3FN3OS: C, 




Yield 85%; m.p.: 250-251°C; buff coloured solid; IR 
(ν, cm
-1
, KBr): 1691(C=O), 1262 (C-F), 1078 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ (ppm) 7.24- 
7.28 (m, 4H, Ar-H), 7.62-7.64 (d, 1H, benzothiazole, 
J = 7.22 Hz), 7.68-7.70 (d, 1H, benzothiazole,  
J = 8.59 Hz), 9. 49 (s, 1H, pyrazole), 9.91 (s, 1H, CHO); 





calcd. for C17H8ClF2N3OS: C, 54.34; H, 2.15; N, 
11.18. Found: C, 54.36; H, 2.17, N, 11.16. 
 
Synthesis of compound 12a-c 
To a mixture of 11(a-c) (0.01 mol), isoniazid  
(0.01 mol) and 2-3 drops of glacial acetic acid in dry 
toluene to a 100 mL round bottom flask, reflux it for 
24 h in Dean-Stark apparatus. The reaction was 
monitored by TLC. After completion of the reaction, 
solid separated out on cooling, was filtered and 
recrystallized from toluene.  
N'-((1-(7-Chloro-6-fluorobenzo[d]thiazol-2-yl)-
3-phenyl-1H-pyrazol-4-yl)methylene)isonicotine 
hydrazide, 12a: Yield 82%; m.p.: 228-230°C; off 
white solid; IR (ν, cm
-1
, KBr): 3454 (NH), 1652 
(C=O), 1560 (N=CH), 1205 (C-F), 1037 (C-Cl);  
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 7.81-7.82 
(d, 2H, pyridine, J = 8.82Hz), 7.31-7.36 (m, 5H, ArH), 
8.21(s, 1H, NH), 7.68-7.70 (d, 1H, benzothiazole,  
J = 7.23 Hz), 7.75-7.77 (d, 1H, benzothiazole,  
J = 7.69 Hz), 8.57 (s, 1H, N=CH), 8.77-8.78 (m, 2H, 
pyridine), 8.97 (s, 1H, pyrazole), 12.08 (s, 1H, NH); 
13
C NMR (400 MHz, DMSO-d6) δ ppm; 161.23 
(C=O), 160.54 (C-2 of benzothiazole), 154.07 (C-F of 
benzothiazole), 150.47 (C-2 of pyridine), 150.29 (C-6 
of pyridine), 147.38 (C-4 of benzothiazole), 140.65 
(CH=N), 140.24 (C-3 of pyrazole), 132.85 (C-4 of 
pyridine), 130.46 (C-9 of benzothiazole), 129.46 (C-5 
of pyrazole), 128.84 (C-3 of pyridine), 128.52 (C-5 of 
pyridine), 128.26 (C-4 of pyrazole), 127.26 (C-Cl of 
benzothiazole), 123.32 (C-1 of Ar), 121.41 (C-2 of 
Ar), 121.26 (C-6 of Ar), 119.53 (C-3 of Ar), 119.34 
(C-5 of Ar), 119.05 (C-4 of Ar), 110.70 (C-6 of 
benzothiazole), 110.43 (C-5 of benzothiazole); ESI-




; Anal. calcd. 
for C23H14ClFN6OS: C, 57.92; H, 2.96; N, 17.62. 
Found: C, 57.90; H, 2.98, N, 17.60. 
N'-((1-(7-Chloro-6-fluorobenzo[d]thiazol-2-yl)-
3-(2,4-dichlorophenyl)-1H-pyrazol-4-yl) methylene) 
isonicotinohydrazide, 12b: Yield 82%; m.p.: 260-
262°C; light brown coloured solid; IR (ν, cm
-1
, KBr): 
3450 (NH), 1692 (C=O), 1565 (N=CH), 1167 (C-F), 
977 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 
7.85-7.87 (d, 2H, pyridine, J = 8.56Hz), 7.31-7.36 (d, 
2H, ArH, J = 9.53 Hz), 7.58 (s, 1H, ArH), 8.25(s, 1H, 
NH), 7.66-7.68 (d, 1H, benzothiazole, J = 7.26 Hz), 
7.75-7.76 (d, 1H, benzothiazole, J = 7.65 Hz), 8.51  
(s, 1H, N=CH), 8.70-8.72 (m, 2H, pyridine), 8.99  





; Anal. calcd. for 
C23H12Cl3FN6OS: C, 50.61; H, 2.22; N, 19.49. Found: 
C, 50.62; H, 2.25, N, 19.47. 
N'-((1-(7-Chloro-6-fluorobenzo[d]thiazol-2-yl)-
3-(4-fluorophenyl)-1H-pyrazol-4-yl) methylene) 
isonicotinohydrazide, 12c: Yield 89%; m.p.: 325-
326°C; off white solid; IR (ν, cm
-1
, KBr): 3397 (NH), 
1696 (C=O), 1600 (N=CH), 1224 (C-F), 1076 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 7.37-7.41 
(t, 2H, ArH, J = 8.84 Hz and 8.88 Hz), 7.80-7.81 (d, 
2H, pyridine), 7.87-7.91 (q, 2H, ArH), 7.61-7.63 (d, 
1H, benzothiazole, J = 7.24 Hz), 7.69-7.70 (d, 1H, 
benzothiazole, J = 8.68 Hz), 8.54 (s, 1H, N=CH), 
8.77-8.78 [d, 2H, (pyridine)], 9.00 (s, 1H, pyrazole) 





; Anal. calcd. for C23H13ClF2N6OS: C, 
55.82; H, 2.65; N, 16.98. Found: C, 55.76; H, 2.68,  
N, 16.97. 
 
Synthesis of compound 13a-c 
A mixture of compound 7, (2.626 g, 0.01 mol) and 
substituted acetophenone (0.01 mol) in methanol  
(30 mL) containing 2-3 drop of glacial acetic acid was 
refluxed for 0.5 h. After completion of the reaction, 
the solid that separated out on cooling, was filtered 
and recrystallized by methanol. 
7-Chloro-6-fluoro-5-nitro-2-(2-(1-phenylethylidene) 
hydrazinyl)benzo[d]thiazole, 13a: Yield 94%; m.p.: 
212-214°C; colourless crystal; IR (ν, cm
-1
, KBr): 3432 
(NH), 1615 (N=C), 1194 (C-F), 1011 (C-Cl); 
1
H 
NMR (400 MHz, DMSO-d6), δ (ppm): 2.30 (s, 3H, 
CH3), 7.50-7.46 (m, 5H, ArH), 7.93-7.96 (d, 1H, 
benzothiazole, J = 7.60 Hz), 10.76 (s, 1H, NH); ESI-




; Anal. calcd. 
for C15H10ClFN4O2S: C, 49.39; H, 2.76; N, 15.36. 
Found: C, 49.36; H, 2.78, N, 15.34. 
7-Chloro-2-(2-(1-(2,4-dichlorophenyl)ethylidene) 
hydrazinyl)-6-fluoro-5-nitrobenzo[d]thiazole, 13b: 




Yield 85%; m.p.: 205-206°C; off white crystal;  
IR (ν, cm
-1
, KBr): 3321 (N-H), 1537 (NO2), 1612 
(N=C), 1222 (C-F), 1091 (C-Cl); 
1
H NMR (400 MHz, 
DMSO-d6), δ (ppm): 2.33 (s, 3H, CH3), 7.42 (s, 1H, 
ArH), 7.32-7.35 (d, 2H, ArH), 7.94-7.97 (d, 1H, 
benzothiazole, J = 7.61 Hz), 10.45 (s, 1H, NH); ESI-




; Anal. calcd. 
for C15H8Cl3FN4O2S: C, 41.54; H, 1.86; N, 12.92. 
Found: C, 41.38; H, 1.88, N, 12.91. 
7-Chloro-6-fluoro-2-(2-(1-(4-fluorophenyl) 
ethylidene)hydrazinyl)-5-nitrobenzo[d]thiazole, 
13c: Yield 84%; m.p.: 230-232°C; off white crystal; 
IR (ν, cm
-1
, KBr): 3469 (N-H), 1606 (N=C), 1546 
(NO2), 1193 (C-F), 1012 (C-Cl); 
1
H NMR (400 MHz, 
DMSO-d6), δ (ppm): 2.36 (s, 3H, CH3), 7.41-7.44 (m, 
4H, ArH), 7.93-7.95 (d, 1H, benzothiazole, J = 7.65 





; Anal. calcd. for C15H9ClF2N4O2S: C, 
47.07; H, 2.37; N, 14.64. Found: C, 47.02; H, 2.34, N, 
14.62. 
 
Synthesis of compound 14a-c 
To the Vilsmeier-Haack reagent prepared from 
DMF (10 mL) and POCl3 (1.1 mL, 0.012 mol),  
7-chloro-6-fluoro-5-nitro-2-(2-(1-substitutedphenyl 
ethylidene)hydrazinyl)benzo [d] thiazole 13(a-c) 
(0.01 mol) was added and the reaction mixture was 
stirred at 60-65°C for 3 h. The reaction was monitored 
by TLC. After completion of the reaction, the mixture 
was poured in to ice cold water. The solid that 
separated on neutralization with NaHCO3 was 
filtered, washed with water and recrystallized by 
DMF-water. 
1-(7-Chloro-6-fluoro-5-nitrobenzo[d]thiazol-2-yl)- 
3-phenyl-1H-pyrazole-4-carbaldehyde, 14a: Yield 
72%; m.p.: 230-232°C; off white crystal; IR (ν, cm
-1
, 
KBr): 1691 (C=O), 1546 (NO2), 1205 (C-F), 1076  
(C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 
7.29-7.32 (m, 5H, ArH), 7.92-7.94 (d, 1H, 
benzothiazole, J =7.67 Hz), 9.43 (s, 1H, pyrazole), 





; Anal. calcd. for C17H8ClFN4O3S: C, 50.69; 
H, 2.00; N, 13.91. Found: C, 50.66; H, 2.00, N, 13.90. 
1-(7-Chloro-6-fluoro-5-nitrobenzo[d]thiazol-2-yl)- 
3-(2,4-dichlorophenyl)-1H-pyrazole-4-carbaldehyde, 
14b: Yield 67%; m.p.: 215-217°C; garish granular; IR 
(ν, cm
-1
, KBr): 1695 (C=O), 1542 (NO2), 1201 (C-F), 
1072 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ 
(ppm): 7.32-7.35 (m, 3H, ArH), 7.91-7.94 (d, 1H, 
benzothiazole, J = 7.70 Hz), 9.42 (s, 1H, pyrazole), 





; Anal. calcd. for C17H6Cl3FN4O3S: C, 43.29; 
H, 1.28; N, 11.88. Found: C, 43.23; H, 1.32, N, 11.84. 
1-(7-Chloro-6-fluoro-5-nitrobenzo[d]thiazol-2-yl)- 
3-(4-fluorophenyl)-1H-pyrazole-4-carbaldehyde, 14c: 
Yield 69%; mp 262-264°C; off white crystal; IR  
(ν, cm
-1
, KBr): 1691 (C=O), 1543 (NO2), 1224 (C-F), 
1045 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ 
(ppm): 7.23-7.27 (m, 4H, ArH), 7.91-7.93 (d, 1H, 
benzothiazole, J = 7.65 Hz), 9.44 (s, 1H, pyrazole), 





; Anal. calcd. for C17H7ClF2N4O3S: C, 48.52; 
H, 1.68; N, 13.32. Found: C, 48.50; H, 1.69, N, 13.30. 
 
Synthesis of compound 15a-c 
To a mixture of compound 14(a-c) (0.01 mol), 
isoniazid 1.371 g (0.01 mol) and 2-3 drops of glacial 
acetic acid in dry toluene to a 100 mL round bottom 
flask, reflux it for 24 h in Dean-Stark apparatus. The 
reaction was monitored by TLC. After completion of 
the reaction, solid that separated out on cooling, was 
filtered and recrystallized by toluene.  
N'-((1-(7-Chloro-6-fluoro-5-nitrobenzo[d] 
thiazol-2-yl)-3-phenyl-1H-pyrazol-4-yl)methylene) 
isonicotinohydrazide, 15a: Yield 77%; m.p.: 302-
304°C; light yellow granular; IR (ν, cm
-1
, KBr): 3472 
(NH), 1654 (C=O), 1535 (NO2), 1606 (N=CH), 1222 
(C-F), 1070 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), 
δ (ppm): 7.35-7.38 (m, 5H, ArH), 7.93-7.95 (d, 1H, 
benzothiazole, J = 7.67 Hz), 7.98-8.00 (d, 2H, 
pyridine, J = 8.83 Hz), 8.57 (s, 1H, -N=CH), 8.75-
8.78 [m, 2H, (pyridine, J = 8.88 Hz)], 8.98 (s, 1H, 
pyrazole), 12.07 (s, 1H, NH); 
13
C NMR (400 MHz, 
DMSO-d6) δ ppm: 161.26 (C=O), 160.54 (C-2 of 
benzothiazole), 158.29 (C-F of benzothiazole), 156.29 
(C-2 of pyridine), 156.07 (C-6 of pyridine), 150.70 
(C-4 of benzothiazole), 150.29 (CH=N), 147.38 (C-3 
of pyrazole), 140.90 (C-4 of pyridine), 140.24 (C-9 of 
benzothiazole), 132.85 (C-5 of pyrazole), 132.43 (C-3 
of pyridine), 130.46 (C-5 of pyridine), 129.46 (C-NO2 
of benzothiazole), 128.85 (C-4 of pyrazole), 128.52 
(C-1 of Ar), 128.26 (C-2 of Ar), 127.26 (C-6 of Ar), 
123.32 (C-3 of Ar), 121.41 (C-5 of Ar), 121.26 (C-4 
of Ar), 119.53 (C-5 of benzothiazole), 110.43 (C-Cl 





; Anal. calcd. for C23H13ClFN7O3S: C, 52.93; 
H, 2.51; N, 18.79. Found: C, 52.95; H, 2.54, N, 18.76. 
N'-((1-(7-Chloro-6-fluoro-5-nitrobenzo[d] 
thiazol-2-yl)-3-(2,4-dichlorophenyl)-1H-pyrazol-4-yl) 
methylene)isonicotinohydrazide, 15b: Yield 71%; 




m.p.: 292-294°C; whitish amorphous powder; IR  
(ν, cm
-1
, KBr): 3385 (N-H), 1697 (C=O), 1610 
(N=CH), 1537 (NO2), 1222 (C-F), 971 (C-Cl);  
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 7.36-7.39 
(m, 3H, ArH), 7.92-7.93 (d, 1H, benzothiazole,  
J = 7.66 Hz), 7.97-7.99 (d, 2H, pyridine, J = 8.83 Hz), 
8.48 (s, 1H, N=CH), 8.77-8.78 [m, 2H, (pyridine,  
J = 8.80 Hz))], 8.98 (s, 1H, pyrazole), 12.09 (s, 1H, 





calcd. for C23H11Cl3FN7O3S: C, 46.76; H, 1.88; N, 
16.60. Found: C, 46.71; H, 1.84, N, 16.62. 
N'-((1-(7-Chloro-6-fluoro-5-nitrobenzo[d] 
thiazol-2-yl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl) 
methylene)isonicotinohydrazide, 15c: Yield 70%; 
m.p.: 325-327°C; light yellow amorphous powder; IR 
(ν, cm
-1
, KBr): 3476 (N-H), 1641 (C=O), 1610 
(N=CH), 1537 (NO2), 1222 (C-F), 1017 (C-Cl); 
1
H 
NMR (400 MHz, DMSO-d6), δ (ppm): 7.37-7.41 (m, 
4H, ArH), 7.92-7.94 (d, 1H, benzothiazole, J = 7.62 Hz), 
7.98-7.80 (d, 2H, pyridine, J = 8.83 Hz), 8.54 (s, 1H, 
N=CH), 8.77-8.78 [d, 2H, (pyridine, J = 8.89 Hz))], 





; Anal. calcd. for 
C23H12ClF2N7O3S: C, 51.17; H, 2.24; N, 18.16. 
Found: C, 51.19; H, 2.28, N, 18.13. 
 
Synthesis of compound 16a-c 
A mixture of compound 8, (2.626 g, 0.01 mol)  
and substituted acetophenone (0.01 mol) in methanol 
(30 mL) containing 2-3 drop of glacial acetic acid was 
refluxed for 0.5 h. The reaction was monitored by 
TLC. After completion of the reaction, solid separated 
out on cooling, was filtered and recrystallized from 
methanol. 
7-Chloro-6-fluoro-4-nitro-2-(2-(1-phenylethylidene) 
hydrazinyl)benzo[d] thiazole, 16a: Yield 87%; m.p.: 
244-246°C; white crystal; IR (ν, cm
-1
, KBr): 3330  
(N-H), 1615 (N=C), 1540 (NO2), 1191 (C-F), 1045 
(C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 
2.31 (s, 3H, CH3), 7.45-7.48 (m, 5H, ArH), 8.38-8.40 
(d, 1H, benzothiazole, J = 9.41 Hz), 10.86 (s, 1H, NH); 




; Anal. calcd. for 
C15H10ClFN4O2S: C, 49.39; H, 2.76; N, 15.36. Found: 
C, 49.41; H, 2.75, N, 15.35. 
7-Chloro-2-(2-(1-(2,4-dichlorophenyl)ethylidene) 
hydrazinyl)-6-fluoro-4-nitrobenzo[d] thiazole, 16b: 
Yield 81%; mp 236-238°C; off white crystal; IR  
(ν, cm
-1
, KBr): 3321 (N-H), 1612 (N=C), 1537 (NO2), 
1193 (C-F), 1041 (C-Cl); 
1
H NMR (400 MHz, 
DMSO-d6), δ (ppm): 2.30 (s, 3H, CH3), 7.44-7.49 (m, 
3H, ArH), 8.39-8.41 (d, 1H, benzothiazole, J = 9.42 Hz), 





; Anal. calcd. for C15H8Cl3FN4O2S: C, 41.54; 
H, 1.86; N, 12.92. Found: C, 41.53; H, 1.85, N, 12.90. 
7-Chloro-6-fluoro-2-(2-(1-(4-fluorophenyl) 
ethylidene)hydrazinyl)-4-nitrobenzo[d]thiazole, 16c: 
Yield 85%; m.p.: 274-276°C; white crystal; IR (ν, cm
-1
, 
KBr): 3462 (N-H), 1608 (N=C), 1546 (NO2), 1193 
(C-F), 1078 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), 
δ (ppm): 2.29 (s, 3H, CH3), 7.43-7.47 (m, 4H, ArH), 
8.38-8.40 (d, 1H, benzothiazole, J = 9.42 Hz), 10.84 





; Anal. calcd. for C15H9ClF2N4O2S: C, 47.07; 
H, 2.37; N, 14.64. Found: C, 47.05; H, 2.36, N, 14.65. 
 
Synthesis of compound 17a-c 
To the Vilsmeier-Haack reagent prepared  
from DMF (10 mL) and POCl3 (1.1 mL, 0.012 mol), 
7-chloro-6-fluoro-5-nitro-2-(2-(1-substituted 
phenylethylidene)hydrazinyl)benzo [d] thiazole (16a-c) 
(0.01 mol) was added and the reaction mixture was 
stirred at 60-65°C for 3 h. The reaction was monitored 
by TLC. After completion of the reaction, the mixture 
was poured in to ice cold water. The solid that 
separated on neutralization with NaHCO3 was 
filtered, washed with water and recrystallized by 
DMF-water. 
1-(7-Chloro-6-fluoro-4-nitrobenzo[d]thiazol-2-yl)- 
3-phenyl-1H-pyrazole-4-carbaldehyde, 17a: Yield 
72%; m.p.: 270-272°C; gray coloured crystal; IR (ν, 
cm
-1
, KBr): 1691 (C=O), 1537 (NO2), 1205 (C-F), 
1035 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), δ 
(ppm): 7.30-7.34 (m, 5H, ArH), 8.41-8.43 (d, 1H, 
benzothiazole, J = 9.26 Hz), 9.60 (s, 1H, pyrazoline), 





; Anal. calcd. for C17H8ClFN4O3S: C, 




17b: Yield 64%; m.p.: 290-292°C; off white crystal; 
1
H NMR (400 MHz, DMSO-d6), δ (ppm): 7.35-7.39 
(m, 3H, ArH), 8.42-8.44 (d, 1H, benzothiazole, J = 
9.46 Hz), 9.59 (s, 1H, pyrazoline), 9.98 (s, 1H, CHO); 





calcd. for C17H6Cl3FN4O3S: C, 43.29; H, 1.28; N, 
11.88. Found: C, 43.28; H, 1.30, N, 11.87. 
1-(7-Chloro-6-fluoro-4-nitrobenzo[d]thiazol-2-yl)- 
3-(4-fluorophenyl)-1H-pyrazole-4-carbaldehyde, 17c: 
Yield 61%; m.p.: 302-304°C; gray coloured crystal; 






, KBr): 1691 (C=O), 1543 (NO2), 1207  
(C-F), 1083 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), 
δ (ppm): 7.33-7.37 (m, 4H, ArH), 8.42-8.44 (d, 1H, 
benzothiazole, J = 9.46 Hz), 9.58 (s, 1H, pyrazoline), 





; Anal. calcd. for C17H7ClF2N4O3S: C, 
48.52; H, 1.68; N, 13.32. Found: C, 48.51; H, 1.65, N, 
13.29. 
 
Synthesis of compound 17a-c 
To a mixture of compound 17(a-c) (0.01 mol), 
isoniazid 1.371 g (0.01 mol) and 2-3 drops of glacial 
acetic acid in dry toluene to a 100 mL round bottom 
flask, reflux it for 24 h in Dean-Stark apparatus. The 
reaction was monitored by TLC. After completion of 
the reaction, solid separated out on cooling, was filter 
and recrystallized by toluene.  
N'-((1-(7-Chloro-6-fluoro-4-nitrobenzo[d] 
thiazol-2-yl)-3-phenyl-1H-pyrazol-4-yl) methylene) 
isonicotinohydrazide, 18a: Yield 77%; m.p.: 300-
302°C; light yellow crystal; IR (ν, cm
-1
, KBr): 3471 
(N-H), 1696 (C=O), 1602 (N=CH), 1537 (NO2), 1211 
(C-F), 1031 (C-Cl); 
1
H NMR (400 MHz, DMSO-d6), 
δ (ppm): 7.34-7.38 (m, 5H, ArH), 7.68-7.69 (d, 2H, 
pyridine, J = 9.01 Hz), 8.49-8.52 (d, 1H, 
benzothiazole, J = 8.71 Hz), 8.74 (s, 1H, N=CH), 
9.13-9.15 (d, 2H, pyridine, J = 9.01 Hz), 9.38 (s, 1H, 





; Anal. calcd. for 
C23H13ClFN7O3S: C, 52.93; H, 2.51; N, 18.79. Found: 
C, 52.91; H, 2.50, N, 18.78. 
N'-((1-(7-Chloro-6-fluoro-4-nitrobenzo[d] 
thiazol-2-yl)-3-(2,4-dichlorophenyl)-1H-pyrazol-4-yl) 
methylene)isonicotinohydrazide, 18b: Yield 68%; 
m.p.: 308-310°C; light yellow crystal; IR (ν, cm
-1
, 
KBr): 3446 (N-H), 1696 (C=O), 1610 (N=CH), 1537 
(NO2), 1224 (C-F), 1074 (C-Cl); 
1
H NMR (400 MHz, 
DMSO-d6), δ (ppm): 7.32-7.37 (m, 3H, ArH), 7.72-
7.74 (d, 2H, pyridine, J = 9.05 Hz), 8.52-8.54 (d, 1H, 
benzothiazole, J = 8.75 Hz), 8.75 (s, 1H, N=CH), 
9.15-9.16 (d, 2H, pyridine, J = 9.05 Hz), 9.39 (s, 1H, 





; Anal. calcd. for 
C23H11Cl3FN7O3S: C, 46.76; H, 1.88; N, 16.60. 
Found: C, 46.77; H, 1.89, N, 16.57. 
N'-((1-(7-Chloro-6-fluoro-4-nitrobenzo[d] 
thiazol-2-yl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl) 
methylene)isonicotinohydrazide, 18c: Yield 77%; 
m.p.: 325-327°C; off white crystal; IR (ν, cm
-1
, KBr): 
3169 (N-H), 1656 (C=O), 1606 (N=CH), 1537 (NO2), 
1224 (C-F), 1027 (C-Cl); 
1
H NMR (400 MHz, 
DMSO-d6), δ (ppm): 7.37-7.41 (m, 4H, ArH), 7.62-
7.65 (d, 2H, pyridine, J = 9.24 Hz), 8.54-8.57 (d, 1H, 
benzothiazole, J = 8.18 Hz), 8.74 (s, 1H, N=CH), 
9.07-9.09 (d, 2H, pyridine, J = 9.24 Hz), 9.41 (s, 1H, 





; Anal. calcd. for 
C23H12ClF2N7O3S: C, 51.17; H, 2.24; N, 18.16. 
Found: C, 51.19; H, 2.23, N, 18.17. 
 
Antitubercular activity 
The ability of compounds to inhibit the growth  
of Mycobacterium species was determined by  
Ziehl-Neelsen stain which was grown in Middlebrook 
7H-9 broth. The standard strain Mycobacterium 
tuberculosis H37Rv (ATCC 27294) was used. The 
basal medium was prepared according to 
manufacturer’s instructions (Hi-Media) and sterilized 
by autoclaving. 4.5 mL of broth were taken into each 
sterile bottles to that 0.5 mL of ADC supplement was 
added which contains catalase, dextrose and bovine 
serum albumin fraction. Then compound solution 
was then transferred to media bottles to achieve final 
concentrations 25, 50, 100 µg/ mL. Finally 10 µL 
suspension of Mycobacterium tuberculosis strain 
(100000 organisms/ mL, adjusted by McFarland's 
turbidity standard) was transferred to each of the 
tubes and were incubated at 37°C for three weeks. 
One control without compound as well as drug was 
also set up and was inspected for growth twice a 
week. The appearance of turbidity was considered as 
growth and indicates resistance to the compound. The 
growth was confirmed by making a smear from each 
bottle and performing a Ziehl-Neelsen stain.  
 
In vitro cytotoxicity evaluation 
 
Chemicals 
3-(4, 5–dimethyl thiazol–2–yl)–5–diphenyl 
tetrazolium bromide (MTT), Fetal Bovine serum 
(FBS), Phosphate Buffered Saline (PBS), RPMI-1640 
medium (RPMI) and Trypsin were obtained from 
Sigma Aldrich Co, St Louis, USA. EDTA, Glucose 
and antibiotics from Hi-Media Laboratories Ltd., 
Mumbai. 
 
Cell lines and culture medium 
THP-1 (Human, Monocytes) cell cultures were 
procured from National Centre for Cell Sciences 
(NCCS), Pune, India. Stock cells of THP-1 was 
cultured in RPMI, supplemented with 10% inactivated 
Fetal Bovine Serum (FBS), penicillin (100 IU/ mL), 




streptomycin (100 g/ mL) and amphotericin B  
(5 g/ mL) in a humidified atmosphere of 5% CO2 at 
37 C until confluent. The cells were dissociated with 
TPVG solution (0.2% trypsin, 0.02% EDTA, 0.05% 
glucose in PBS). For THP-1 cells, the confluent cell 
suspension was centrifuged at 2000 rpm for 10 min and 
the cell pellet was resuspended in fresh medium. The 
stock cultures were grown in 25 cm
2
 culture flasks and 
all experiments were carried out in 96 microtitre plates 
(Tarsons India Pvt. Ltd., Kolkata, India). 
 
Preparation of test solutions 
For cytotoxicity studies, each weighed test drugs 
were separately dissolved in distilled DMSO and 
volume was made up with RPMI supplemented with 
2% inactivated FBS to obtain a stock solution of  
1 mg/ mL concentration and sterilized by filtration. 
Serial two fold dilutions were prepared from this for 
carrying out cytotoxic studies. 
 
Cytotoxicity (CTC50) THP-1 cell lines 
Procedure with THP-1 culture: The cell 
suspension from the confluent culture flask was 
transferred to sterile tubes, centrifuged at 2000 rpm 
for 10 min and cell pellet was separated. Known 
volume of media was added to the pellet and cells 
were resuspended and cell count was adjusted to 1.0 
x 10
5 
cells/ mL using RPMI-1640 medium 
containing 10% fetal bovine serum. To each well of 
the 96 well microtitre plate, 0.1 mL of the diluted 
cell suspension (approximately 10,000 cells) was 
added. After 2 h, 100 L of different test 
concentrations of test drugs were added on to the 
partial monolayer in microtitre plates. The plates 
were then incubated at 37°C for 3 days in 5% CO2 
atmosphere, and microscopic examination was 
carried out and observations were noted every 24 h 
interval. After 72 h, 10 L of 3-(4, 5–dimethyl 
thiazol–2–yl)–5–diphenyl tetrazolium bromide 
(MTT) (5 mg/ mL) in phosphate buffered saline was 
added to each well. The plates were gently shaken 
and incubated for 3 h at 37°C in 5% CO2 
atmosphere. Microtitre plates were centrifuged at 
2000 rpm for 15 min and supernatant was removed. 
100 L of propanol was added and the plates  
were gently shaken to solubilise the formed 
formazan. The absorbance was measured using a 
microplate reader at a wavelength of 540 nm.  
The percentage growth inhibition was calculated 
using the following formula and concentration  
of test drug needed to inhibit cell growth by 50% 
(CTC50) values is generated from the dose-response 







Benzothiazole derivatives and there nitro 
regioisomers combined with pyrazoles attached with 
isoniazid for better antitubercular activity. Nine final 
compounds has been synthesised and there in vitro 
antimycobacterial activity on Mycobacterium 
tuberculosis H37Rv (ATCC 27294) has shown the 
compounds 15a, 15b, 15c, 18b and 18c are potent 
anti-tubercular agents (MIC = 40.19 to 64.96 nM). In 
vitro cytotoxicity studies on mammalian THP-1 
(Human, Monocytes) cell line and CTC50 value was 
calculated. Presence of a nitro group in the compound 
is shown to increase the toxicity, though this 
concentration is far more than the concentration tested 
for the antitubercular activity. 
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